Expression and Prognostic Significance of LAG-3, TIGIT, VISTA, and IDO1 in Endometrial Serous Carcinoma
View abstract on PubMed
Summary
This summary is machine-generated.Immune checkpoint markers lymphocyte-activation gene 3 (LAG-3) and T-cell immunoglobulin and ITIM domain (TIGIT) expression in endometrial serous carcinoma (ESC) correlates with better survival. High TIGIT expression independently predicts improved overall survival in these aggressive tumors.
Area Of Science
- Oncology
- Immunology
- Cancer Research
Background
- Endometrial serous carcinoma (ESC) is an aggressive cancer with limited immunotherapy research.
- Immune checkpoint blockade shows promise for endometrial carcinomas, but ESC-specific targets are understudied.
Purpose Of The Study
- To investigate the expression and prognostic value of immune checkpoints LAG-3, TIGIT, VISTA, and IDO1 in ESC.
- To correlate these markers with CD8+ and FOXP3+ tumor-infiltrating lymphocytes (TILs).
Main Methods
- Analysis of 94 ESC cases for expression of LAG-3, TIGIT, VISTA, and IDO1.
- Correlation of marker expression with CD8+ and FOXP3+ TIL densities.
- Kaplan-Meier survival analysis and multivariate analysis for prognostic value.
Main Results
- LAG-3, TIGIT, and VISTA showed positive correlations with each other and with CD8+ and FOXP3+ TILs.
- High LAG-3 and TIGIT expression correlated with improved progression-free survival (PFS) and overall survival (OS).
- High TIGIT expression was an independent predictor of better OS in multivariate analysis.
Conclusions
- LAG-3, TIGIT, and VISTA play roles in the ESC tumor microenvironment.
- Their expression patterns suggest complex immune interactions and potential immunogenicity in a subset of ESC.
- Further research is needed to fully understand immune components in ESC and their association with tumor properties.

